Vinay Prasad, a former epidemiology professor at the University of California at San Francisco, has been appointed as the new director of the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA). In his new role, Prasad will be responsible for overseeing the regulation of vaccines, gene therapies, and the blood supply.
Prasad, who holds a medical degree from the University of Chicago and has trained in oncology and hematology at prestigious institutions such as the National Cancer Institute and the National Institutes of Health, brings a wealth of experience and expertise to his new position. Despite his impressive credentials, Prasad has been known for his critical views of the medical mainstream, including the FDA.
The announcement of Prasad’s appointment was made by FDA Commissioner Marty Makary in a Tuesday email to staff. He will be taking over from former CBER director Peter Marks, who was forced to resign by health secretary Robert F. Kennedy, Jr. in March.
Prasad’s appointment comes at a crucial time, as the FDA continues to play a pivotal role in ensuring the safety and efficacy of biologic products. With his background in epidemiology and oncology, Prasad is well-equipped to navigate the complexities of regulating cutting-edge therapies such as gene therapies and vaccines.
As the new director of CBER, Prasad will be tasked with upholding the highest standards of regulatory oversight while also fostering innovation in the biologics industry. His appointment represents a fresh perspective at the FDA and signals a commitment to addressing the evolving challenges in biologics regulation.
Overall, Vinay Prasad’s appointment as the director of CBER marks an important milestone in the FDA’s efforts to safeguard public health and advance the field of biologics. His unique background and critical approach to medicine are expected to bring a fresh perspective to the agency’s regulatory efforts.
